CAR T cell immunotherapy for human cancer
Explore this paper's citation graph
Summary
Opportunities and challenges for entering mainstream oncology that presently face the CAR T field are described, with a focus on the challenges that have emerged over the past several years.
- Type
- review
- Published
- 2018-03-23
- Cited by
- 2,749
- References
- 69
- OpenAlex
- https://openalex.org/W2792588868
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4189854
Keywords
Chimeric antigen receptor, Lymphoma, Adoptive immunotherapy, Immunotherapy, Adoptive cell transfer
References
- CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- Different affinity windows for virus and cancer-specific T-cell receptors – implications for therapeutic strategies
- NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma
- Engineering CAR-T Cells: Design Concepts
- Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent anti-tumor activity
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
- Toxicity management for patients receiving novel T-cell engaging therapies
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
- Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased anti-leukemic efficacy in vivo
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
- Adoptive cell transfer as personalized immunotherapy for human cancer
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions.
- Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.
- A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
- Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
- Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Cited by
- Which biological systems should be engineered?
- Prospects of immunotherapy for cancer
- Applications of Molecular Engineering in T-cell-based Immunotherapies
- A stochastic individual-based model to explore the role of spatial interactions and antigen recognition in the immune response against solid tumours.
- Establishing CD19 B-cell reference control materials for comparable and quantitative cytometric expression analysis
- Vγ9Vδ2 T cells - response to P. falciparum-derived phosphoantigens and potential for use in colon cancer immunotherapy
- Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.
- Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
- Adoptive T cell cancer therapy
- Immunotherapy of primary brain tumors: facts and hopes
- Ctrl-Alt-inDel: genome editing to reprogram a cell in the clinic.
- Intracellular delivery of colloids: Past and future contributions from microinjection
- Cancer stemness, intratumoral heterogeneity, and immune response across cancers
- Macrophage targeting: opening new possibilities for cancer immunotherapy
- Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy
- Chimeric Antigen Receptor Therapy
- Traceable Bioinspired Nanoparticle for the Treatment of Metastatic Breast Cancer via NIR‐Trigged Intracellular Delivery of Methylene Blue and Cisplatin
- CAR T cells for infection, autoimmunity and allotransplantation
- Cancer immune therapy for lymphoid malignancies: recent advances
- CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
Related papers
- Current status and problems of chimeric antigen receptor T cell immunotherapy in treatment of hematological malignancies
- The present situation and prospect of CAR-T cellular immunotherapy
- CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements
- Adoptive cellular immunotherapy for cancer
- Adoptive immunotherapy.
- Cellular adoptive immunotherapy after bone marrow transplantation.
- Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
- B7-H3/CD276: An Emerging Cancer Immunotherapy